Iovance Biotherapeutics, Inc. ( IOVA ) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer October 29, 2026 8:30 AM EDT

Company Participants

Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications

Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director

Conference Call Participants

Lin Tsai - Jefferies LLC, Research Division

Yanan Zhu - Wells Fargo Securities, LLC, Research Division

Etzer Darout - Barclays Bank PLC, Research Division

Nicholas Lorusso - TD Cowen, Research Division

Jack Allen - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Operator

Welcome to the Iovance Biotherapeutics conference call to review updated data from the IOV-LUN-202 trial in non-small cell lung cancer. My name is Carmen.…